For twenty-one years, an FDA file sat on a sunscreen filter the rest of the developed world had been wearing to the beach. Europe approved bemotrizinol in 1999. Australians, who live under one of the most punishing UV indexes on earth, have had it the entire stretch, and it is widely used across Japan and South Korea. The American application landed in 2005 and stayed in the queue.

It cleared on Tuesday. The agency added bemotrizinol (sold as Parsol Shield by the Dutch manufacturer dsm-firmenich) to the over-the-counter sunscreen monograph at concentrations up to six percent, the first new active sunscreen ingredient approved in the US since the late 1990s. The same FDA had spent the same twenty-one years unable to say most of the filters Americans were actually using were safe.

The 2019 proposed monograph put numbers on the gap. Of sixteen active sunscreen ingredients on the US market, only two, zinc oxide and titanium dioxide, had enough data to be Generally Recognized as Safe and Effective. Two more were flagged for safety concerns. The other twelve, including most of the organic filters in actual American sunscreens, were proposed not-GRASE because the safety data the agency wanted did not exist. The country had been slathering them on its kids for decades while its own regulator could not call them safe and effective.

Compare the molecule the FDA just approved. Bemotrizinol gives you one stable broad-spectrum filter where the current US chemical lineup needs a cocktail to do the same job. Avobenzone, the only meaningful UVA-coverage filter in that lineup, photodegrades in sunlight; an unstabilized formulation can lose a significant fraction of its UVA protection inside the first hour of UV exposure while the SPF number on the bottle stays the same. Bemotrizinol does not. It is a 627-dalton molecule, large enough that very little of it crosses skin, and it stays intact when it absorbs a photon. It also stabilizes other filters in the bottle, which is why European formulators have built their broad-spectrum lineups around it for two decades. The European cosmetics safety committee reviewed it in 1998 and found low percutaneous absorption and no signal of skin irritation, photo-mutagenicity, or photo-clastogenicity. Twenty-seven years of use across two continents have not surfaced an FDA-cited safety concern sufficient to keep it off the monograph.

Meanwhile the US data on what Americans had been using was getting worse. In 2019 Murali Matta and colleagues published a randomized maximal-use trial in JAMA. Twenty-four healthy adults applied four commercial sunscreens containing avobenzone, oxybenzone, octocrylene, or ecamsule to 75 percent of their bodies, four times a day, for four days. Plasma concentrations of all four ingredients passed the FDA’s own 0.5 ng/mL threshold on day one, the level at which the agency itself wants additional toxicology data before deciding a filter is safe. Oxybenzone was the worst, with mean peak plasma levels several hundred times that threshold. The trial did not prove the filters harm anyone, but it did show, in the agency’s own pages, that the safety questions the FDA had been deferring for decades were measurable on day one of normal use.

The queue is the rest of the story. Congress tried to fix it in 2014 with the Sunscreen Innovation Act, which set deadlines for FDA review of the eight backlogged filter applications. No filter cleared in the years that followed. By 2019 the agency was demanding the kind of maximal-use absorption trial its own scientists had just published showing the existing chemical filters would not pass. dsm-firmenich ran new studies. Nothing actually moved until the CARES Act of 2020 quietly attached an OTC monograph reform to the pandemic relief bill, replacing rulemaking with administrative orders and adding the user fees the FDA needed to staff the work. Under that pathway, bemotrizinol went from proposed order in December 2025 to final order on June 9, 2026. Seven months. The previous twenty years required two acts of Congress.

dsm-firmenich now holds eighteen months of US market exclusivity on the ingredient, after which any sunscreen maker can formulate with it. Parsol Shield is expected on US shelves later this year. The Environmental Working Group, which has been pushing the FDA on absorption data behind filters like oxybenzone for years, told CBS News the agency had long left Americans with outdated sunscreen technology and that the new approval was a major win for US consumers.

I came into this story expecting the usual regulatory-delay tale and finished it more skeptical, not less. The mineral-only crowd, the wellness-skeptical parents who got told they were being paranoid about American chemical sunscreens, were reading the FDA’s own data correctly. The fix took twenty-one years not because the science was hard but because the agency tasked with photoprotection was structurally unable to add a better filter that the rest of the developed world had been using since the Clinton administration. Congress had to legislate around the process twice. That is not capture in the political-payoff sense. It is process rot of the kind that costs decades.

What happens next is the test of whether the new pathway actually works. Older filter applications behind bemotrizinol are still unresolved, several of them ingredients Europe approved more than a decade ago. The seven-month turnaround on this one is the agency’s chance to prove the new system clears the next file too. The eighteen-month exclusivity window matters as well. Until generic formulators can use bemotrizinol freely in late 2027, the lower-cost drugstore sunscreens most Americans grab on the way out of Walmart will likely keep the same old filter lineup, which means the people who buy on price will still be using the chemistry the FDA’s own 2019 review could not call safe and effective. If you are shopping today, the only two sunscreen ingredients the FDA has ever been willing to call safe and effective are still zinc oxide and titanium dioxide. As of Tuesday, bemotrizinol joins them. The other twelve are still where they have been for years, in regulatory limbo, on store shelves, on your skin.

Sources

  1. FDA – “FDA Expands Sunscreen Options for the First Time in 20 Years,” press announcement, June 9, 2026
  2. Matta et al. – “Effect of Sunscreen Application Under Maximal Use Conditions on Plasma Concentration of Sunscreen Active Ingredients,” JAMA, 2019
  3. FDA – “Sunscreen Drug Products for Over-the-Counter Human Use,” proposed monograph, Federal Register, February 26, 2019
  4. CBS News – “New sunscreen ingredient wins FDA approval after years of delay”
  5. Environmental Working Group – “The Trouble with Ingredients in Sunscreen,” EWG’s Guide to Sunscreens
  6. Holland & Knight – “FDA Proposes First New Sunscreen Ingredient in Decades,” December 2025